CU20210088A7 - Compuestos derivados sustituidos de indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) - Google Patents
Compuestos derivados sustituidos de indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)Info
- Publication number
- CU20210088A7 CU20210088A7 CU2021000088A CU20210088A CU20210088A7 CU 20210088 A7 CU20210088 A7 CU 20210088A7 CU 2021000088 A CU2021000088 A CU 2021000088A CU 20210088 A CU20210088 A CU 20210088A CU 20210088 A7 CU20210088 A7 CU 20210088A7
- Authority
- CU
- Cuba
- Prior art keywords
- virus
- hbv
- indol
- active against
- substituted derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
<p>La presente invención se refiere, en general, a compuestos derivados sustituidos de indol-2-carboxamidas activas, útiles para prevenir o tratar la infección del virus de la hepatitis B de fórmula general (I)</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>Específicamente, estos compuestos pueden inhibir la proteína o proteínas codificada (s) por el virus de la hepatitis B (VHB) o interferir con la función del ciclo de replicación del VHB. La invención se refiere asimismo a composiciones que comprenden estos compuestos y a procesos o intermedios para fabricarlos.</p>
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19172005 | 2019-04-30 | ||
EP19172398 | 2019-05-02 | ||
PCT/EP2020/061948 WO2020221826A1 (en) | 2019-04-30 | 2020-04-29 | Novel indole-2-carboxamides active against the hepatitis b virus (hbv) |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20210088A7 true CU20210088A7 (es) | 2022-06-06 |
Family
ID=70391142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2021000088A CU20210088A7 (es) | 2019-04-30 | 2020-04-29 | Compuestos derivados sustituidos de indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220306647A1 (es) |
EP (1) | EP3962914A1 (es) |
JP (1) | JP2022530522A (es) |
KR (1) | KR20220004131A (es) |
CN (1) | CN113767101A (es) |
AU (1) | AU2020267015A1 (es) |
BR (1) | BR112021021564A2 (es) |
CA (1) | CA3138643A1 (es) |
CL (1) | CL2021002799A1 (es) |
CU (1) | CU20210088A7 (es) |
EC (1) | ECSP21079317A (es) |
IL (1) | IL287278A (es) |
MX (1) | MX2021013085A (es) |
SG (1) | SG11202111236UA (es) |
TW (1) | TWI770501B (es) |
UY (1) | UY38682A (es) |
WO (1) | WO2020221826A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2023005983A (es) | 2020-11-23 | 2023-08-15 | Enanta Pharm Inc | Nuevos agentes antivirales derivados de la espiropirrolidina. |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19817264A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
AU4289100A (en) | 1999-03-25 | 2000-10-16 | Bayer Aktiengesellschaft | Dihydropyrimidines and their use in the treatment of hepatitis |
EP1189501B1 (en) | 1999-04-23 | 2007-02-28 | Extenday IP Limited | Sheet fastening and anchoring component |
WO2001045712A1 (de) | 1999-12-22 | 2001-06-28 | Bayer Aktiengesellschaft | Arzneimittelkombinationen gegen virale erkrankungen |
CA2568389A1 (en) | 2004-06-09 | 2005-12-22 | Merck & Co., Inc. | Hiv integrase inhibitors |
WO2006033995A2 (en) | 2004-09-16 | 2006-03-30 | Valeant Research And Development | Thiazolidin-4-ones having anti-hepatitis b activity |
CN106166157B (zh) | 2011-07-01 | 2019-08-02 | 巴鲁·S·布隆伯格研究所 | 作为防乙型肝炎病毒感染的抗病毒剂的氨磺酰苯甲酰胺衍生物 |
ES2649410T3 (es) | 2011-12-21 | 2018-01-11 | Novira Therapeutics Inc. | Agentes antivirales para la hepatitis B |
AU2013207205B2 (en) | 2012-01-06 | 2017-02-02 | Janssen Sciences Ireland Uc | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of Hepatitis B |
US9096579B2 (en) * | 2012-04-20 | 2015-08-04 | Boehringer Ingelheim International Gmbh | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments |
KR102122244B1 (ko) | 2012-08-28 | 2020-06-15 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도 |
NZ704758A (en) | 2012-08-28 | 2018-06-29 | Janssen Sciences Ireland Uc | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b |
WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
WO2014184328A1 (en) | 2013-05-17 | 2014-11-20 | F. Hoffmann-La Roche Ag | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
EA035500B1 (ru) | 2013-05-17 | 2020-06-25 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b |
LT3024819T (lt) | 2013-07-25 | 2018-06-11 | Janssen Sciences Ireland Uc | Pirolamido dariniai, turintys glioksamido pakaitų, ir jų panaudojimas kaip vaistų hepatito b gydymui |
CN105828823B (zh) | 2013-10-18 | 2019-06-14 | 美国印第安纳大学研究和技术公司 | 乙型肝炎病毒组装效应物 |
CN106255684B (zh) | 2013-11-14 | 2019-08-23 | 诺维拉治疗公司 | 氮杂环庚烷衍生物和治疗乙型肝炎感染的方法 |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
KR101933844B1 (ko) | 2014-03-07 | 2018-12-28 | 에프. 호프만-라 로슈 아게 | B형 간염 바이러스 감염의 치료 및 예방을 위한 6-융합된 헤테로아릴다이하이드로피리미딘 |
WO2015138895A1 (en) | 2014-03-13 | 2015-09-17 | Indiana University Research And Technology Corporation | Hepatitis b core protein allosteric modulators |
AU2015236982B2 (en) | 2014-03-28 | 2017-12-14 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and their application in pharmaceuticals |
CA2948580A1 (en) | 2014-05-09 | 2015-11-12 | Adam Zlotnick | Methods and compositions for treating hepatitis b virus infections |
MX2017001862A (es) | 2014-08-14 | 2017-05-15 | Hoffmann La Roche | Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b. |
WO2016089990A1 (en) | 2014-12-02 | 2016-06-09 | Novira Therapeutics, Inc. | Sulfide alkyl and pyridyl reverse sulfonamide compounds for hbv treatment |
MX2017008720A (es) | 2014-12-30 | 2018-01-25 | Novira Therapeutics Inc | Derivados y metodos para tratamiento de las infecciones por hepatitis b. |
MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
KR20170113658A (ko) | 2015-03-16 | 2017-10-12 | 에프. 호프만-라 로슈 아게 | Tlr7 작용제 및 hbv 캡시드 조립 억제제를 사용하는 병용 치료 |
WO2016161268A1 (en) | 2015-04-01 | 2016-10-06 | Enanta Pharmaceuticals, Inc. | Hepatitis b antviral agents |
US10273228B2 (en) | 2015-04-17 | 2019-04-30 | Indiana University Research And Technology Corporation | Hepatitis B viral assembly effectors |
JP6462155B2 (ja) | 2015-05-04 | 2019-01-30 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | B型肝炎ウイルス感染症の治療用のHBsAg(HBV表面抗原)及びHBV DNA産生の阻害剤としてのテトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類 |
WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10179131B2 (en) | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
CN107849037B (zh) | 2015-07-21 | 2020-04-17 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的三环4-吡啶酮-3-甲酸衍生物 |
WO2017015451A1 (en) | 2015-07-22 | 2017-01-26 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
TWI721016B (zh) | 2015-09-15 | 2021-03-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
AU2016330964B2 (en) | 2015-09-29 | 2021-04-01 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
ES2794639T3 (es) | 2015-11-04 | 2020-11-18 | Qilu Pharmaceutical Co Ltd | Forma cristalina, método de preparación y compuesto intermedio de compuesto con anillo dihidropirido |
US10280175B2 (en) | 2016-02-02 | 2019-05-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
CA3017020C (en) | 2016-03-07 | 2024-01-16 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
WO2017173999A1 (zh) | 2016-04-06 | 2017-10-12 | 陈焕明 | 抗乙肝病毒的吡唑-噁唑烷酮类化合物 |
CN109153682B (zh) | 2016-05-20 | 2021-05-25 | 豪夫迈·罗氏有限公司 | 用于治疗感染性疾病的具有氧、硫和氮连接基的新的吡嗪化合物 |
CN114057739A (zh) * | 2016-06-29 | 2022-02-18 | 诺维拉治疗公司 | 二氮杂酮衍生物及其在治疗乙型肝炎感染中的用途 |
WO2018011160A1 (en) | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
WO2018011163A1 (en) * | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
EP3484885B1 (en) | 2016-07-14 | 2020-03-04 | H. Hoffnabb-La Roche Ag | Carboxy 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
US11001564B2 (en) | 2016-09-13 | 2021-05-11 | Arbutus Biopharma Corporation | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same |
SG11201908012SA (en) | 2017-03-02 | 2019-09-27 | Assembly Biosciences Inc | Cyclic sulfamide compounds and methods of using same |
EP3601216B1 (en) | 2017-03-21 | 2023-10-25 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection |
JP7123429B2 (ja) | 2017-05-04 | 2022-08-23 | シャンハイ ロングウッド バイオファルマシューティカルズ カンパニー リミテッド | 二環式縮合環系ヌクレオカプシド阻害剤および薬物としてb型肝炎を治療するためのその使用 |
WO2019020070A1 (zh) | 2017-07-27 | 2019-01-31 | 江苏恒瑞医药股份有限公司 | 哌嗪并杂芳基类衍生物、其制备方法及其在医药上的应用 |
TW201912153A (zh) | 2017-08-30 | 2019-04-01 | 加拿大商愛彼特生物製藥公司 | 用於治療b型肝炎的化合物、醫藥組合物及方法 |
US10759774B2 (en) | 2017-09-28 | 2020-09-01 | The Curators Of The University Of Missouri | Inhibitors of hepatitis B virus targeting capsid assembly |
SG11202003700TA (en) * | 2017-11-02 | 2020-05-28 | Aicuris Gmbh & Co Kg | Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv) |
EP3704119A1 (en) * | 2017-11-02 | 2020-09-09 | AiCuris GmbH & Co. KG | Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv) |
-
2020
- 2020-04-29 WO PCT/EP2020/061948 patent/WO2020221826A1/en unknown
- 2020-04-29 MX MX2021013085A patent/MX2021013085A/es unknown
- 2020-04-29 BR BR112021021564A patent/BR112021021564A2/pt not_active IP Right Cessation
- 2020-04-29 CU CU2021000088A patent/CU20210088A7/es unknown
- 2020-04-29 SG SG11202111236UA patent/SG11202111236UA/en unknown
- 2020-04-29 JP JP2021564278A patent/JP2022530522A/ja active Pending
- 2020-04-29 EP EP20720857.0A patent/EP3962914A1/en not_active Withdrawn
- 2020-04-29 CA CA3138643A patent/CA3138643A1/en active Pending
- 2020-04-29 AU AU2020267015A patent/AU2020267015A1/en not_active Abandoned
- 2020-04-29 US US17/607,605 patent/US20220306647A1/en active Pending
- 2020-04-29 KR KR1020217038545A patent/KR20220004131A/ko unknown
- 2020-04-29 CN CN202080032420.1A patent/CN113767101A/zh active Pending
- 2020-04-30 TW TW109114654A patent/TWI770501B/zh active
- 2020-05-04 UY UY0001038682A patent/UY38682A/es unknown
-
2021
- 2021-10-14 IL IL287278A patent/IL287278A/en unknown
- 2021-10-25 CL CL2021002799A patent/CL2021002799A1/es unknown
- 2021-10-26 EC ECSENADI202179317A patent/ECSP21079317A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3138643A1 (en) | 2020-11-05 |
EP3962914A1 (en) | 2022-03-09 |
MX2021013085A (es) | 2021-11-17 |
AU2020267015A1 (en) | 2021-12-23 |
SG11202111236UA (en) | 2021-11-29 |
WO2020221826A1 (en) | 2020-11-05 |
TW202106687A (zh) | 2021-02-16 |
UY38682A (es) | 2020-11-30 |
JP2022530522A (ja) | 2022-06-29 |
US20220306647A1 (en) | 2022-09-29 |
BR112021021564A2 (pt) | 2022-01-04 |
IL287278A (en) | 2021-12-01 |
CN113767101A (zh) | 2021-12-07 |
CL2021002799A1 (es) | 2022-06-10 |
KR20220004131A (ko) | 2022-01-11 |
ECSP21079317A (es) | 2021-11-30 |
TWI770501B (zh) | 2022-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020004838A (es) | Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb). | |
MX2020004839A (es) | Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb). | |
BR112018071678A2 (pt) | compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv | |
CL2020000487A1 (es) | Agentes antivirales contra la hepatitis b. | |
UY38434A (es) | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) | |
CU20210037A7 (es) | Compuestos derivados sustituidos de urea 6,7-dihidro-4h-pirazolo [1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) | |
CL2021001117A1 (es) | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
ECSP21078893A (es) | Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb) | |
CU20210088A7 (es) | Compuestos derivados sustituidos de indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
UY38435A (es) | Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) | |
CU20210090A7 (es) | Compuestos derivados de oxalil piperazinas activos contra el virus de la hepatitis b (vhb) | |
UY38439A (es) | Novedosas urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) | |
UY38681A (es) | Nuevas indolizina-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
EA202192967A1 (ru) | Новые индол-2-карбоксамиды, активные против вируса гепатита b (вгв) | |
EA202192969A1 (ru) | Новые оксалилпиперазины, активные против вируса гепатита b (вгв) | |
EA202192968A1 (ru) | Новые фенил- и пиридилмочевины, активные против вируса гепатита b (вгв) | |
EA202192965A1 (ru) | Новые индолизин-2-карбоксамиды, активные против вируса гепатита b (вгв) |